GeneCentric Therapeutics Announces New US Patent Granted for Molecular Characterization of Non-Squam ...
LEARN MORE
GeneCentric's rT(I)ME Explorer Platform
Unwinding the complex Tumor and Immune MicroEnvironment (T(I)ME) to translate tumor biology insights into actionable genomic signatures of drug response and new target identification. Our RNA-based rT(I)ME Explorer Platform builds upon pioneering RNA-based genomic-defined cancer subtypes and immunogenomic innovations.
The rT(I)ME Explorer Platform is designed to characterize tumor biology in a manner that enables optimal targeting of therapeutic compounds through the combination of gene expression data with disease-related molecular pathways and immune cell expression to identify therapy response signatures using advanced computational biology technologies.
LEARN MORE
Cancer Profiler Portfolio Powered by the rT(I)ME Explorer Platform
GeneCentric is building a pipeline of universal cancer subtypes/response signatures across areas of target biology and for the most prevalent and complex cancers with high unmet medical need.
LEARN MORE
Achieving Greater Progress Through Effective Collaboration
GeneCentric is proud to collaborate with some of the world’s leading research and development organizations. By bringing together our unique strengths and proprietary technology with that of our partners we are able to rapidly and efficiently translate the most promising science and advance drug development, delivering new hope to those fighting cancer today.
LEARN MOREGeneCentric Adds Unique Value at Every Stage of Drug Development
Development Stage Involvement
Drive translational research to FIM through novel in-silico and in-vivo modeling
Enable clear segmentation of patients via subtyping during early drug development
Confirm subtype profilers as response biomarkers supporting accelerated drug, and companion diagnostic, development
Expand subtypes drug-response biomarkers in confirmatory and indication expansion studies to maximize market potential
Reposition and repurpose drugs by subtyping patients to reveal new or additional drug responder populations and commercial potential
Making News: Our Latest Progress, Partnerships and Impact
GeneCentric Therapeutics Announces the Appointment of Philippe Chemla, PhD, MBA, as Chief Business O ...
LEARN MORE
GeneCentric Therapeutics Enters into Research Collaboration with Janssen on Genomic Drug Response Bi ...
LEARN MORE